AstraZeneca Gets US License for Imfinzi Lung-Cancer Drug
29 Novembre 2019 - 08:43AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC (AZN.LN) said Friday that a supplemental
biologics license application and granted priority review for the
Imfinzi drug, which fights against untreated extensive-stage
small-cell lung cancer, has been accepted by the U.S. Food and Drug
Administration.
The drug maker said a prescription-drug user fee act date--the
deadline for the FDA to review the application--is set for the
first quarter of 2020.
Small-cell lung cancer is an aggressive, fast-growing form of
lung cancer that recurs and progresses rapidly, the London-listed
company said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 29, 2019 02:28 ET (07:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2023 a Mar 2024